DK1296998T3 - HCV-varianter - Google Patents
HCV-varianterInfo
- Publication number
- DK1296998T3 DK1296998T3 DK01937697.9T DK01937697T DK1296998T3 DK 1296998 T3 DK1296998 T3 DK 1296998T3 DK 01937697 T DK01937697 T DK 01937697T DK 1296998 T3 DK1296998 T3 DK 1296998T3
- Authority
- DK
- Denmark
- Prior art keywords
- hcv
- variants
- methods
- expression vectors
- polynucleotides
- Prior art date
Links
- 238000000034 method Methods 0.000 abstract 3
- 108091033319 polynucleotide Proteins 0.000 abstract 3
- 102000040430 polynucleotide Human genes 0.000 abstract 3
- 239000002157 polynucleotide Substances 0.000 abstract 3
- 239000013604 expression vector Substances 0.000 abstract 2
- 108091026890 Coding region Proteins 0.000 abstract 1
- 108010076039 Polyproteins Proteins 0.000 abstract 1
- 241000288906 Primates Species 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 239000003937 drug carrier Substances 0.000 abstract 1
- 230000001939 inductive effect Effects 0.000 abstract 1
- 208000015181 infectious disease Diseases 0.000 abstract 1
- 230000002401 inhibitory effect Effects 0.000 abstract 1
- 230000010076 replication Effects 0.000 abstract 1
- 238000001890 transfection Methods 0.000 abstract 1
- 229960005486 vaccine Drugs 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/70—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving virus or bacteriophage
- C12Q1/701—Specific hybridization probes
- C12Q1/706—Specific hybridization probes for hepatitis
- C12Q1/707—Specific hybridization probes for hepatitis non-A, non-B Hepatitis, excluding hepatitis D
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/53—DNA (RNA) vaccination
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/24011—Flaviviridae
- C12N2770/24211—Hepacivirus, e.g. hepatitis C virus, hepatitis G virus
- C12N2770/24222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/24011—Flaviviridae
- C12N2770/24211—Hepacivirus, e.g. hepatitis C virus, hepatitis G virus
- C12N2770/24241—Use of virus, viral particle or viral elements as a vector
- C12N2770/24243—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/24011—Flaviviridae
- C12N2770/24211—Hepacivirus, e.g. hepatitis C virus, hepatitis G virus
- C12N2770/24251—Methods of production or purification of viral material
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2840/00—Vectors comprising a special translation-regulating system
- C12N2840/20—Vectors comprising a special translation-regulating system translation of more than one cistron
- C12N2840/203—Vectors comprising a special translation-regulating system translation of more than one cistron having an IRES
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2840/00—Vectors comprising a special translation-regulating system
- C12N2840/20—Vectors comprising a special translation-regulating system translation of more than one cistron
- C12N2840/203—Vectors comprising a special translation-regulating system translation of more than one cistron having an IRES
- C12N2840/206—Vectors comprising a special translation-regulating system translation of more than one cistron having an IRES having multiple IRES
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- General Health & Medical Sciences (AREA)
- Virology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Medicinal Chemistry (AREA)
- Immunology (AREA)
- Biotechnology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Engineering & Computer Science (AREA)
- Communicable Diseases (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Biophysics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Microbiology (AREA)
- Biomedical Technology (AREA)
- Physics & Mathematics (AREA)
- Gastroenterology & Hepatology (AREA)
- Oncology (AREA)
- Plant Pathology (AREA)
- Analytical Chemistry (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Catalysts (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Transition And Organic Metals Composition Catalysts For Addition Polymerization (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US09/576,989 US7049428B1 (en) | 1998-03-04 | 2000-05-23 | HCV variants |
| PCT/US2001/016822 WO2001089364A2 (en) | 2000-05-23 | 2001-05-23 | Hcv variants |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DK1296998T3 true DK1296998T3 (da) | 2011-12-12 |
Family
ID=24306833
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK01937697.9T DK1296998T3 (da) | 2000-05-23 | 2001-05-23 | HCV-varianter |
Country Status (9)
| Country | Link |
|---|---|
| EP (1) | EP1296998B1 (enExample) |
| JP (2) | JP4095303B2 (enExample) |
| AT (1) | ATE525384T1 (enExample) |
| AU (1) | AU2001263407B9 (enExample) |
| CA (1) | CA2409873C (enExample) |
| DK (1) | DK1296998T3 (enExample) |
| ES (1) | ES2373642T3 (enExample) |
| IL (3) | IL152671A0 (enExample) |
| WO (1) | WO2001089364A2 (enExample) |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7235394B1 (en) | 1995-08-29 | 2007-06-26 | Washington University | Functional DNA clone for hepatitis C virus (HCV) and uses thereof |
| ES2287074T3 (es) * | 2000-12-22 | 2007-12-16 | Boehringer Ingelheim (Canada) Ltd. | Molecula de rna autorreplicante del virus de la hepatitis c. |
| EP2050822B1 (en) * | 2001-01-23 | 2013-07-31 | Istituto Di Ricerche Di Biologia Molecolare P. Angeletti S.P.A. | Hepatitis C virus replicons and replicon enhanced cells |
| ES2321498T3 (es) * | 2002-03-11 | 2009-06-08 | Lab 21 Limited | Metodos y composiciones para identificar y caracterizar la hepatitis c. |
| ATE426682T1 (de) * | 2002-04-16 | 2009-04-15 | Merck & Co Inc | Hepatitis-c-virus-testsysteme |
| KR100502864B1 (ko) * | 2002-10-09 | 2005-07-22 | (주)팬바이오넷 | Ｃ형 간염바이러스의 복제 정량 리플리콘, 이를 포함하는세포주, 및 상기 세포주를 이용한 ｈｃｖ 저해제의 탐색방법 |
| CA2505551A1 (en) * | 2002-11-13 | 2004-05-27 | Washington University | Highly permissive cell lines for hepatitis c virus replication |
| DE602004024658D1 (de) | 2003-02-13 | 2010-01-28 | Merck & Co Inc | Verfahren zur vermittlung von zellkulturreplikationsaktivität an unterschiedliche hepatitis-c-virus-isolate |
| JP4342519B2 (ja) * | 2003-09-22 | 2009-10-14 | 株式会社グリーンペプタイド | Ｃ型肝炎ウイルス由来ペプチド |
| EP1685238A4 (en) | 2003-11-05 | 2008-08-20 | Merck & Co Inc | HCV REPLICONS WITH NS5B GENOTYP 2B |
| KR100894150B1 (ko) * | 2004-06-25 | 2009-04-22 | 가부시끼가이샤 센단세메이가가꾸겐큐죠 | 신규한 배열을 가진 ｈｃｖ ｒｎａ |
| GB0421908D0 (en) | 2004-10-01 | 2004-11-03 | Angeletti P Ist Richerche Bio | New uses |
| CN101688197A (zh) * | 2007-04-27 | 2010-03-31 | 株式会社先端生命科学研究所 | Hcv基因 |
| GB0716292D0 (en) | 2007-08-21 | 2007-09-26 | Biofocus Dpi Ltd | Imidazopyrazine compounds |
| WO2009079185A2 (en) * | 2007-11-26 | 2009-06-25 | Novartis Vaccines And Diagnostics, Inc. | Methods of generating alphavirus particles |
| EP2558117A4 (en) * | 2010-04-12 | 2013-11-13 | Viracine Therapeutics Corp | EXPRESSION OF POSITIVELY SENSING INTRODUCING RNA VIRUSES AND USES THEREOF |
| EP2917340A1 (en) | 2012-11-07 | 2015-09-16 | Gilead Sciences, Inc. | Hcv genotype 6 replicons |
| CN112225783B (zh) * | 2020-09-16 | 2021-08-31 | 东莞市朋志生物科技有限公司 | Hcv重组抗原及其突变体 |
-
2001
- 2001-05-23 DK DK01937697.9T patent/DK1296998T3/da active
- 2001-05-23 ES ES01937697T patent/ES2373642T3/es not_active Expired - Lifetime
- 2001-05-23 WO PCT/US2001/016822 patent/WO2001089364A2/en not_active Ceased
- 2001-05-23 IL IL15267101A patent/IL152671A0/xx unknown
- 2001-05-23 EP EP01937697A patent/EP1296998B1/en not_active Expired - Lifetime
- 2001-05-23 AU AU2001263407A patent/AU2001263407B9/en not_active Ceased
- 2001-05-23 JP JP2001585612A patent/JP4095303B2/ja not_active Expired - Lifetime
- 2001-05-23 CA CA2409873A patent/CA2409873C/en not_active Expired - Lifetime
- 2001-05-23 AT AT01937697T patent/ATE525384T1/de not_active IP Right Cessation
-
2002
- 2002-11-06 IL IL152671A patent/IL152671A/en active IP Right Grant
-
2006
- 2006-07-06 IL IL176731A patent/IL176731A/en active IP Right Grant
- 2006-12-18 JP JP2006339705A patent/JP2007143553A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| JP2007143553A (ja) | 2007-06-14 |
| AU6340701A (en) | 2001-12-03 |
| WO2001089364A9 (en) | 2003-07-10 |
| IL176731A0 (en) | 2006-10-31 |
| CA2409873C (en) | 2013-01-08 |
| JP4095303B2 (ja) | 2008-06-04 |
| CA2409873A1 (en) | 2001-11-29 |
| WO2001089364A2 (en) | 2001-11-29 |
| EP1296998B1 (en) | 2011-09-21 |
| JP2003533232A (ja) | 2003-11-11 |
| AU2001263407B9 (en) | 2007-05-24 |
| IL152671A0 (en) | 2003-06-24 |
| ATE525384T1 (de) | 2011-10-15 |
| WO2001089364A3 (en) | 2003-01-23 |
| EP1296998A4 (en) | 2009-01-28 |
| AU2001263407B2 (en) | 2006-12-07 |
| ES2373642T3 (es) | 2012-02-07 |
| IL152671A (en) | 2009-09-01 |
| EP1296998A2 (en) | 2003-04-02 |
| IL176731A (en) | 2009-12-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU6340701A (en) | Hcv variants | |
| HUP0000992A2 (hu) | Sejttenyészetben szaporodni képes, géntechnológiailag módosított, fertőző nyálkatömlő-betegséget okozó vírus (IBDV) mutánsai | |
| ES2020152A4 (es) | Diagnosticos y vacunas para nanbv. | |
| TR199901602T2 (xx) | Serin proteazlar�n ve �zel olarak hepatit C vir�s� NS3 proteaz�n�n inhibit�rleri. | |
| MXPA02010551A (es) | Formulaciones y metodos de uso de mimeticos del oxido nitrico contra fenotipos de celulas malignas. | |
| AU4203201A (en) | Methods of suppressing hepatitis virus infection using immunomodulatory polynucleotide sequences | |
| WO2003104411A3 (en) | BIOARTIFICIAL LIVER SYSTEM | |
| ES2128756T3 (es) | Conmutador de proximidad con sensor un sensible al campo magnetico. | |
| PL373992A1 (en) | Method for the cultivation of primary cells and for the amplification of viruses under serum free conditions | |
| Lijuan et al. | An avirulent Micropterus salmoides rhabdovirus vaccine candidate protects Chinese perch against rhabdovirus infection | |
| GB9925955D0 (en) | Hcv n33 protease inhibitors | |
| ATE355375T1 (de) | Bakterioferritin aus helicobacter pylori | |
| AR014772A1 (es) | Una formulacion acuosa que permite la estabilizacion de conjugados de peg-interferon alfa durante y despues de la liofilizacion, proceso para producir un polvo liofilizado, un polvo liofilizado, un proceso para producir una solucion de los conjudados peg-interferon-alfa y un articulo de manufactura | |
| UA84667C2 (ru) | Вакцина, направленная против инфекции, вызванной вирусом герпеса болезни марека | |
| DE60231821D1 (de) | Rekombinante tollwut-vakzine und verfahren zu ihrer herstellung und verwendung | |
| TW200509964A (en) | VP1 of foot-and-mouth disease virus | |
| WO2001012215A3 (en) | Protective antigen of Epstein barr virus | |
| CN212254483U (zh) | 一种智能电压力锅性能测试装置 | |
| CY1107374T1 (el) | Εμβολιο ιχθυος εναντι της piscirickettsia salmonis | |
| DE60045663D1 (de) | Rlichem interferon-alpha | |
| Xiao-Yong et al. | Where are the RNA vaccines for TB? | |
| AR035809A1 (es) | Cromosomas artificiales que comprenden secuencias de ehv | |
| WO2004065408A3 (en) | Enhancement of humoral immune responses using a novel myeloid accessory cell | |
| ES2139549A1 (es) | Vacuna anti-flexibacter maritimus (fm-95) para la prevencion de la enfermedad "flexibacteriosis marina" en rodaballo y peces salmonidos, y procedimiento de obtencion. | |
| YIN et al. | Effect of Cyclosporine A on stable established lymphoma models induced by Epstein-Barr virus |